Pfizer's Inlyta drug misses kidney-cancer endpoint; Sanofi wants to turn closed factory into IT hub;

@FiercePharma: Our latest ranking: 10 Largest Settlements and Judgments. Includes those big state deals. More | Follow @FiercePharma

> Pfizer's ($PFE) cancer drug Inlyta fell short in a study in kidney cancer patients, but company officials said it was close, and sub-populations may merit further study. Report

> Sanofi ($SNY) is trying to recruit high-tech companies to develop an IT hub on the site of its factory in Dagenham, England, which is slated for closure as part of a global cost-cutting effort. Report

> Federal prosecutors raided New England Compounding Center, the pharmacy tied to a meningitis outbreak. Report

> Novo Nordisk ($NVO) has contributed more money to U.S. candidates this election cycle--about $176,000--than any other contributor from Denmark. Report

> Richard Roberts, CEO of URL Pharmaceuticals until it was sold to Takeda in June, funded a new political group to support Florida Rep. Allen West; he contributed $1 million to the effort. Report

> The European Union's health commissioner stepped down amid corruption charges related to tobacco products. Report

Biotech News

 @FierceBiotech: Scientists produced stem cells from cadaver scalp tissue. Item | Follow @FierceBiotech

 @JohnCFierce: Looks like Samsung is getting a taste of just how devilishly hard it can be to develop drugs. More | Follow @JohnCFierce

 @RyanMFierce: Charles River is touting a 3-year strategic deal with AstraZeneca, which is outsourcing across the globe. More | Follow @RyanMFierce

> Cebix gains $31M, new CEO as it preps for PhIIb diabetes study. Story

> FDA advisers back NPS Pharma's orphan bowel drug. Article

Medical Device News

 @FierceMedDev: The FDA has slapped its most serious label on Accutron's voluntary flowmeter recall. More | Follow @FierceMedDev

 @MarkHFierce: New device company Cibiem launches with $10M series A. More | Follow @MarkHFierce

 @DamianFierce: AstraZeneca's inked a deal with another CRO, picking Charles River to help speed along its pipeline. More | Follow @DamianFierce

> Quest lowers outlook after Q3 profit drop. Story

> For some, Intuitive Surgical's Q3 20% revenue jump isn't enough. Article

> Analyst: China is primed for a medical device boom. News

Biomarkers News

> Gene variants increase bipolar risk. Article

> Protein marker could cut cost of cancer screening. More

> Gene variant in donated kidneys could mark survival. Report

> Endocyte uses vitamin receptor to tag lung cancer. Story

Drug Delivery News

> Simple anti-HIV vaginal ring delivers three months of protection. Story

> Over the moon? NASA develops motion sickness nasal spray. Item

> Why shape matters in gene delivery. More

> Hiding in plain sight: Using red blood cell proteins to deliver drugs. Article

> Unilife announces new eye delivery platforms. News

And Finally... FDA warned Avon Products about claims made on certain antiwrinkle products, a month after going after L'Oréal's Lancôme unit for similar reasons. Report

Suggested Articles

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.

ICER said that Vertex's triplet CF therapy Trikafta would only be cost effective if the price were dropped from $311,000 to no more than $85,500.